Large ENvue Medical (FEED) insider buy adds 240,000 common shares

Rhea-AI Filing Summary

ENvue Medical 10% owner Christian Michael Glibert bought 240,000 common shares in the open market. The purchase on January 14, 2026 was at a weighted average price of $2.67 per share, with individual trades ranging from $2.47 to $2.90.

Following this transaction, Glibert directly owns 240,000 shares of ENvue Medical common stock. A footnote states that the ownership percentage is calculated against 1,088,192 shares of common stock outstanding as of the issuer’s most recent February 2026 filings, indicating this is a meaningful stake.

Positive

• Significant insider purchase: A 10% owner bought 240,000 ENvue Medical common shares in the open market at a weighted average price of $2.67, creating a sizable direct position relative to the 1,088,192 shares outstanding referenced in the filing.

Negative

• None.

Insights

Equity ownership and insider-trading analyst

Large open-market buy by a 10% owner establishes a significant direct stake.

Christian Michael Glibert, identified as a 10% owner of ENvue Medical, executed an open-market purchase of 240,000 common shares at a weighted average of $2.67 on January 14, 2026. All shares are held as direct ownership after the trade.

The filing notes prices ranged from $2.47 to $2.90, showing the position was built through multiple executions rather than a single block. The ownership percentage reference uses 1,088,192 shares outstanding as of the issuer’s most recent February 2026 filings.

Because this is a purchase rather than a sale, it increases insider exposure to ENvue Medical equity. The scale looks meaningful relative to the stated 1,088,192 outstanding shares, but the long-term significance depends on future disclosures about additional trades or changes in the company’s fundamentals.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Glibert Christian Michael

(Last) (First) (Middle)

4001 GREEN HERON SPRING DRIVE

(Street)

CARPINTERIA CA 93013

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ENvue Medical, Inc. [ FEED ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.001 per share	01/14/2026		P		240,000	A	$2.67(1)	240,000(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.47 to $2.90, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

2. The percentage of ownership is based on 1,088,192 shares of Common Stock outstanding as of the Issuer's most recent filings in February 2026.

	/s/ Christian Michael Glibert	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ENvue Medical (FEED) report for January 14, 2026?

ENvue Medical reported that 10% owner Christian Michael Glibert bought 240,000 common shares on January 14, 2026. The purchase was an open-market transaction at a weighted average price of $2.67 per share, executed across multiple trades within a stated price range.

At what prices did the ENvue Medical (FEED) insider buy 240,000 shares?

The 240,000 ENvue Medical shares were bought at a weighted average price of $2.67. Footnotes explain the purchases occurred in multiple trades, with individual transaction prices ranging from $2.47 to $2.90 per share, inclusive, rather than at a single uniform price.

How many ENvue Medical (FEED) shares does the 10% owner hold after this Form 4 trade?

After the reported transaction, 10% owner Christian Michael Glibert directly holds 240,000 ENvue Medical common shares. The filing shows the entire 240,000-share position as beneficially owned following the open-market purchase on January 14, 2026, with ownership categorized as direct (code D).

How large is the ENvue Medical (FEED) insider’s stake compared to shares outstanding?

A footnote states the ownership percentage is calculated using 1,088,192 ENvue Medical common shares outstanding as of the issuer’s most recent February 2026 filings. The 240,000 directly owned shares therefore represent a substantial portion of the company’s stated outstanding share count.

What does the weighted average price mean in the ENvue Medical (FEED) Form 4?

The weighted average price of $2.67 reflects multiple trades executed between $2.47 and $2.90 per share. The insider notes they will provide full information on the number of shares purchased at each separate price to the issuer, any security holder, or SEC staff upon request.